Sign up
Pharma Capital

Integumen 'tapping into deep vein of pent-up demand' in skincare industry

Integumen PLC’s (LON:SKIN) CEO Gerry Brandon tells Proactive London's Andrew Scott revenues soared by over 1,000% in the first half of the year as blue-chip customers continued to sign up for their cosmetics testing services.

Revenues jumped to £655,000 in the six months to the end of June, compared with just £54,000 a year earlier.


View full SKIN profile View Profile

Integumen's digital revolution

View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.